CENTOGENE Presentations & Investor Relations material

CENTOGENE - transforming genetic data into medical decisions. We are the worldwide leader in the field of early genetic diagnostics for rare hereditary diseases. A database of genetic data from over 110 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. Our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the world's largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development. ImprintCENTOGENE AG is a stock corporation ('Aktiengesellschaft'​) incorporated under the laws of the Federal Republic of Germany with registered seat in Rostock. It is registered with the commercial register of the local court ('Amtsgericht'​) of Rostock under HRB 13225. CENTOGENE AG is CAP (# 8005167) accredited and CLIA (# 99D2049715) registered. Chairman of the Supervisory Board: Dr. Hubert BirnerExecutive Board authorized to represent the company: Prof. Dr. Arndt Rolfs (CEO), Richard Stoffelen (CFO), Prof. Dr. Peter Bauer (CSO), Dr. Volkmar Weckesser (CIO) CENTOGENE AGAm Strande 718055 RostockGermanyTel.: +49 (0) 381 80113 416Fax: 49 (0) 381 80113 401Email: press(at)centogene(dot)comThe Value Added Tax (VAT) identification number (pursuant to Article 22 (1) of the Sixth Council Directive (77/388/EEC) of 17 May 1977 on the harmonization of the laws of the Member States of the European Union relating to turnover taxes) is DE813228872.